Amgen publishes, presents data on therapy with ‘undruggable’ target

Amgen publishes, presents data on therapy with ‘undruggable’ target

Source: 
MedCity News
snippet: 

Sotorasib, a KRAS G12C inhibitor, showed an overall response rate and duration of response that analysts called approvable, but they noted the results have waned over time, and combinations may be the way forward.